Kang M, et al. - Researchers aimed to evaluate the probabilities associated with conditional survival (CS) in patients with metastatic renal cell carcinoma (mRCC) undergoing first-line tyrosine kinase inhibitor (TKI) therapy. In addition, they identified the predictors for CS over time. A retrospective review of clinical data of 1,659 individuals with mRCC from the Korean Renal Cancer Study Group database was performed, and of these, 1,131 were finally analyzed. Patients with mRCC exhibited improved CS over time after initial TKI treatment. Predictors for conditional OS were noted to vary with time. Only previous metastasectomy continued to be a key prognosticator for conditional OS until 36-month survival after initial TKI treatment.